Divergent roles of serum CXCL9 as a biomarker in ILD and COPD: a comparative study
CXCL9 levels correlate with divergent roles in ILD and COPD. It may serve as a prognostic marker, identifying treatable inflammation in ILD and inflammatory burden in COPD.
Authors
- T. Hasegawa
- Huiping Li (ORCID: https://orcid.org/0000-0002-3632-5005)
- Yong Zhang (ORCID: https://orcid.org/0000-0003-2179-3698)
- Xin Kang
- Chengsheng Yin
- Yang Hu
- Jiacui Song
- Ling Yao
Institutions
- Tongji University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Sysmex (Germany) (DE)
- Shanghai Pulmonary Hospital (CN)
- Sysmex (Japan) (JP)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-02-03
- DOI
- https://doi.org/10.3389/fphar.2026.1730688
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sysmex Corporation
- National Natural Science Foundation of China
- Tongji University
- National Key Research and Development Program of China